Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
It is hypothesised that ambrisentan may provide benefit to subjects with inoperable chronic
thromboembolic pulmonary hypertension (CTEPH), where currently no proven or licensed
treatment options exist. This Phase III, randomized, double-blind placebo controlled parallel
group, 16 week study will compare the safety and efficacy of ambrisentan 5 milligrams (mg)
versus placebo in subjects with inoperable CTEPH. The study will enrol 160 subjects, to
assure at least 72 evaluable subjects per treatment arm, based on 10% drop-out rate.